Patents Assigned to INNOPHARMASCREEN INC.
  • Methods and compositions for treatment of asthma or parkinson's disease
    Patent number: 10966943
    Abstract: The present invention relates to methods and compositions comprising proguanil for treating asthma. The invention also relates to methods and compositions comprising proguanil for treating Parkinson's disease.
    Type: Grant
    Filed: September 5, 2019
    Date of Patent: April 6, 2021
    Assignee: INNOPHARMASCREEN INC.
    Inventors: Incheol Kang, Jeseong Park
  • Composition for treatment of inflammatory bowel disease and atopic dermatitis
    Patent number: 10278931
    Abstract: The present invention relates to a compound for inhibiting thymic stromal lymphopoietin (TSLP) secretion from mast cells and use thereof. The compound of the present invention was confirmed to significantly inhibit TSLP secretion from mast cells and, accordingly, may be used as a candidate compound for treating and preventing atopic dermatitis, allergic dermatitis, and/or inflammatory bowel disease.
    Type: Grant
    Filed: October 12, 2016
    Date of Patent: May 7, 2019
    Assignee: INNOPHARMASCREEN INC.
    Inventor: In Cheol Kang
  • METHOD FOR SCREENING OSTEOPONTIN INHIBITOR AND INHIBITOR OBTAINED FROM THE METHOD
    Publication number: 20120264942
    Abstract: Provided is a compound found by screening a material for inhibiting an osteopontin, in which the material for inhibiting the osteopontin can increase effectiveness as an excellent material for inhibiting an osteoporosis.
    Type: Application
    Filed: November 14, 2011
    Publication date: October 18, 2012
    Applicant: INNOPHARMASCREEN, INC.
    Inventors: In-Cheol Kang, Eung-Yoon Kim, Young-Jin Choi
  • METHOD FOR SCREENING INHIBITOR FOR INHIBITING INTERACTION BETWEEN BETA-AMYLOID PEPTIDE AND VEGF AND INHIBITOR SEARCHED BY THE SAME
    Publication number: 20120101284
    Abstract: There is provided a compound found by screening a material for inhibiting a binding between a beta-amyloid 1-42 peptide and VEGF165, in which the inhibition material screened according to the present invention can improve effectiveness as a material for treating Alzheimer's disease.
    Type: Application
    Filed: June 15, 2010
    Publication date: April 26, 2012
    Applicant: INNOPHARMASCREEN INC.
    Inventors: In-Cheol Kang, Chan-Won Park